A two-year-old boy named Miles has become one of the first patients treated with a groundbreaking gene therapy for hereditary hearing loss at Boston Children’s Hospital. This treatment, recently approved by the FDA, targets a specific genetic mutation that prevents sound signals from being transmitted from the inner ear to the brain. Dr. Jeffrey Holt, a leading researcher in gene therapies for hearing loss, likens the condition to a phone that is functional but lacks a proper connection.
In a clinical trial involving 20 participants, 80% experienced improved hearing sensitivity within six months, with 42% achieving normal hearing over time. The therapy, administered via a single injection into the inner ear, delivers a working copy of the mutated otoferlin gene using a dual-vector approach. This innovative method allows the two halves of the gene to recombine within cells, effectively restoring hearing.
Experts emphasize the importance of early treatment, ideally before the age of three, when the brain is most receptive to auditory development. Dr. Daniel Choo, a principal investigator for a related trial, notes that while cochlear implants are currently the standard treatment for hearing loss, gene therapy offers a more natural hearing restoration, potentially leading to better speech and language development.
While gene therapy may not address all forms of hearing loss, researchers are hopeful about future applications. With over 150 genes linked to hearing loss identified, the next target may include the GJB2 gene, which affects a significant percentage of individuals born deaf. The potential for gene therapy to address age-related and noise-induced hearing loss remains uncertain, as these conditions often involve the loss of functional hair cells in the ear. Nonetheless, advancements in gene therapy could transform treatment options for various types of hearing impairments in the coming years.
